Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Revenue of Pharming Group N.V. (PHAR)
Revenue in 2023 (TTM): $245.32 M
According to Pharming Group N.V.'s latest financial reports the company's current revenue (TTM) is $245.32 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Pharming Group N.V.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $245.32 M | $220.1 M | $-2,838,000 | $-12,012,000 | $-10,548,000 |
| 2022 | $205.62 M | $188.06 M | $32.61 M | $14.99 M | $13.67 M |
| 2021 | $189.85 M | $169.67 M | $46.56 M | $22.03 M | $16 M |
| 2020 | $228.39 M | $203.06 M | $92.11 M | $47.47 M | $37.75 M |
| 2019 | $189.33 M | $165.41 M | $75.41 M | $52.29 M | $40.54 M |
| 2018 | $154.58 M | $129.2 M | $50.98 M | $980.32 K | $28.59 M |
| 2017 | $107.52 M | $92.59 M | $-39,814,526 | $-107,252,201 | $-95,924,611 |
| 2016 | $16.69 M | $11.77 M | $-13,946,616 | $-18,442,640 | $-18,442,640 |
| 2015 | $11.84 M | $6.59 M | $-14,747,556 | $-10,886,012 | $-10,886,012 |
| 2014 | $25.76 M | $21.6 M | $3.72 M | $-7,012,744 | $-7,012,744 |
| 2013 | $9.45 M | $7.92 M | $-15,834,461 | $-20,795,935 | $-20,795,935 |
| 2012 | $14.04 M | $8.39 M | $-25,966,091 | $-31,863,147 | $-31,863,147 |
| 2011 | $3.89 M | $-688,225 | $-24,134,534 | $-23,126,175 | $-22,168,362 |
| 2010 | $762.07 K | $641.04 K | $-46,455,646 | $-80,653,012 | $-74,966,086 |
| 2009 | $1.57 M | $1.57 M | $-33,294,172 | $-45,452,461 | $-45,933,864 |
| 2008 | $924.35 K | $924.35 K | $-33,694,351 | $-36,479,940 | $-36,479,940 |
| 2007 | $1.01 M | $-35,897,473 | $-47,895,374 | $-52,324,785 | $-51,922,376 |
| 2006 | $194.01 K | $194.01 K | $-20,703,718 | $-24,478,349 | $-24,411,039 |
| 2005 | $479.68 K | $-5,694,591 | $-19,863,557 | $-21,152,183 | $-21,152,183 |